These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 395066

  • 1. D-Trp8-D-Cys14-somatostatin--demonstration of its differential suppressive activity in juvenile diabetics.
    Neuhaus C, Kerner W, Maier V, Pfeiffer EF.
    Horm Metab Res Suppl; 1979; (8):115-8. PubMed ID: 395066
    [Abstract] [Full Text] [Related]

  • 2. The effect of three days of blood glucose normalization by means of an "artificial endocrine pancreas" on the concentrations of growth hormone, glucagon, and cortisol in juvenile diabetics.
    Schock A, Schultz M, Kerner W, Maier V, Pfeiffer EF.
    Horm Metab Res Suppl; 1979; (8):93-6. PubMed ID: 395097
    [Abstract] [Full Text] [Related]

  • 3. Effect of a somatostatin analog on insulin requirement and hormone levels in 6 insulin-dependent juvenile-onset diabetics subjected to artificial pancreas.
    Lenti G, Trovati M, Lorenzati R, Vitelli F, Tagliaferro V, Marocco A, Pagano G.
    Acta Diabetol Lat; 1980; 17(1):9-14. PubMed ID: 6106342
    [Abstract] [Full Text] [Related]

  • 4. Assessment of daily insulin requirements in diabetics with an artificial endocrine pancreas.
    Lambert AE, Buysschaert M, Lambotte L.
    Horm Metab Res Suppl; 1979; (8):120-7. PubMed ID: 395067
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Influence of continuous physiologic hyperinsulinemia on glucose kinetics and counterregulatory hormones in normal and diabetic humans.
    Saccà L, Sherwin R, Hendler R, Felig P.
    J Clin Invest; 1979 May; 63(5):849-57. PubMed ID: 447832
    [Abstract] [Full Text] [Related]

  • 7. Effect of a 12-hour subcutaneous infusion of somatostatin-14 on blood glucose, insulin and glucagon levels in healthy subjects and insulin dependent diabetics.
    Villaume C, Beck B, Kolopp M, Toussain P, Debry G.
    Biomed Pharmacother; 1986 May; 40(2):61-4. PubMed ID: 2875745
    [Abstract] [Full Text] [Related]

  • 8. Development of specific and non-specific somatostatin analogs.
    Nakano T, Harano Y, Emura J, Kimura T, Sakakibara S, Shigeta Y.
    Horm Metab Res; 1986 Feb; 18(2):98-102. PubMed ID: 2870971
    [Abstract] [Full Text] [Related]

  • 9. The antidiabetic action of somatostatin-28 as assessed by the artificial endocrine pancreas: greater potency than somatostatin-14.
    Hadjidakis DI, Raptis SA, Raptis AE, Karaiskos C, Souvatzoglou A, Diamantopoulos EJ.
    Horm Metab Res; 1987 Nov; 19(11):574-8. PubMed ID: 2892770
    [Abstract] [Full Text] [Related]

  • 10. Route of administration as a factor in the selectivity of hormone suppression of a somatostatin analog in rats.
    Lien EL, Garsky VM.
    Horm Metab Res; 1981 Dec; 13(12):675-8. PubMed ID: 6119282
    [Abstract] [Full Text] [Related]

  • 11. Influence of insulin infusion kinetics of an artificial beta cell on blood glucose control in insulin-dependent diabetics.
    Kerner W, Beischer W, Maier V, Pfeiffer EF.
    Horm Metab Res Suppl; 1979 Dec; (8):71-80. PubMed ID: 395094
    [Abstract] [Full Text] [Related]

  • 12. The external artificial pancreas: an instrument to induce remissions in severe recent juvenile diabetes. Comparison with a preprogrammed insulin infusion system.
    Mirouze J, Selam JL, Pham TC, Orsetti A.
    Horm Metab Res Suppl; 1979 Dec; (8):141-5. PubMed ID: 395071
    [Abstract] [Full Text] [Related]

  • 13. Variation induced by a three-days application of the artificial beta-cell on glucagon, growth hormone and catecholamine secretion, glycosylated hemoglobin, and erythrocyte 2,3-diphosphoglycerate concentration.
    Brunetti P, Massi-Benedetti M, Puxeddu A, Santeusanio F, Calabrese G, Bolli G, Scionti L, Angeletti G.
    Horm Metab Res Suppl; 1979 Dec; (8):81-6. PubMed ID: 395095
    [Abstract] [Full Text] [Related]

  • 14. Effect of insulin-glucose infusions on plasma glucagon levels in fasting diabetics and nondiabetics.
    Raskin P, Fujita Y, Unger RH.
    J Clin Invest; 1975 Nov; 56(5):1132-8. PubMed ID: 1184740
    [Abstract] [Full Text] [Related]

  • 15. [Artificial pancreas: clinical and therapeutic value in 11 patients (author's transl)].
    Buysschaert M, Lambotte L, Lambert AE.
    Nouv Presse Med; 1975 Nov; 8(32):2597-601. PubMed ID: 386266
    [Abstract] [Full Text] [Related]

  • 16. Comparison of a perfusion syringe (Mill Hill Infusor) and a glucose-controlled insulin infusion system in the regulation of diabetes mellitus.
    Stavljenić A, Granić M, Topić B, Skrabalo Z.
    Horm Metab Res Suppl; 1979 Nov; (8):207-11. PubMed ID: 395083
    [Abstract] [Full Text] [Related]

  • 17. Somatostatin--clinical implications.
    Ciba Found Symp; 1976 Nov; 41():313-50. PubMed ID: 780078
    [No Abstract] [Full Text] [Related]

  • 18. Effect of the somatostatin analog D-Trp8,D-Cys14 on glucose insulin, pancreatic glucagon and growth hormone plasma levels in acromegalics and mild diabetics.
    Trovati M, Massara F, Camanni F, Molinatti GM, Lorenzati R, Pagano GF.
    J Endocrinol Invest; 1980 Nov; 3(2):189-92. PubMed ID: 6104680
    [Abstract] [Full Text] [Related]

  • 19. Insulin treatment and state of control before, during, and after connection to a glucose controlled insulin infusion system (Biostator).
    Christiansen JS, Svendsen PA, Deckert T.
    Horm Metab Res Suppl; 1979 Nov; (8):131-4. PubMed ID: 395069
    [Abstract] [Full Text] [Related]

  • 20. Somatostatin and counterregulatory hormone responses to hypoglycaemia in diabetics with and without autonomic neuropathy.
    Fernandez-Castaner M, Webb S, Levy I, Rios M, Casamitjana R, Bergua M, Figuerola D, Rivera F.
    Diabete Metab; 1985 Apr; 11(2):81-6. PubMed ID: 2861121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.